You are here:---Daily News: FDA Halts Marketing of Unapproved Prescription Narcotic Drugs

Daily News: FDA Halts Marketing of Unapproved Prescription Narcotic Drugs

The U.S. Food and Drug Administration warned nine companies to stop manufacturing 14 unapproved narcotic drugs that are marketed in several dosage forms and are widely used to treat pain.

The FDA’s warning letters notified the companies they may be subject to enforcement action if they do not stop manufacturing and distributing prescription unapproved products that include high concentrate morphine sulfate oral solutions and immediate release tablets containing morphine sulfate, hydromorphone, or oxycodone. This action does not include oxycodone capsules.

Those companies receiving warning letters are Boehringer Ingelheim Roxane Inc., Columbus, Ohio; Cody Laboratories Inc., Cody, Wyoming; Glenmark Pharmaceuticals Inc., Mahwah, N.J.; Lannett Company Inc., Philadelphia; Lehigh Valley Technologies Inc., Allentown, Pa.; Mallinckrodt Inc. Pharmaceuticals Group, St. Louis; Physicians Total Care Inc. Tulsa, Okla.; Roxane Laboratories Inc., Columbus, Ohio; and Xanodyne Pharmaceuticals Inc., Newport, Ky.

By | 2009-06-13T00:00:00-04:00 June 13th, 2009|Categories: National|0 Comments

About the Author:

Avatar

Leave A Comment